|
TP53 mutations in myelodysplastic syndromes and secondary AML confer an immunosuppressive phenotype |
Jul 2020 |
Blood |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS) |
|
Genetics of Progression From MDS to Secondary Leukemia |
May 2020 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Clinical decision‐making and treatment of myelodysplastic syndromes |
Oct 2023 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies |
Oct 2023 |
Blood Advances |
Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Myeloproliferative Neoplasms (MPN) |
|
Towards a Conceptualization of Measurable Residual Disease in Myelodysplastic Syndromes |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Determinants of low health-related quality of life in patients with myelodysplastic syndromes: EUMDS Registry study |
Jun 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Health-Related Quality of Life and Vulnerability among People with Myelodysplastic Syndromes: A US National Study |
May 2023 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Long-term efficacy and safety of romiplostim in refractory aplastic anemia: follow-up of a phase 2/3 study |
Dec 2023 |
Blood Advances |
Aplastic Anemia |
|
Guideline-based indicators for adult patients with myelodysplastic syndromes |
Aug 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Venetoclax and Hypomethylating Agents (HMAs) Induce High Response Rates in MDS, Including Patients After HMA Therapy Failure |
Jul 2020 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
